Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

58 results about "Dosing schedules" patented technology

Automated adaptive radiotherapy system with machine learning dose prediction

An automated adaptive radiotherapy system based on machine learning for designing and adapting personalized dosing plans and a corresponding system, the system comprising: • a data acquisition module to collect multimodal patient data such as anatomical images, genomics, physiological signals and electronic health records; • a preprocessing department that performs the normalization, alignment, segmentation and transformation of the acquired data into data structures suitable for predictive modeling; • a dose prediction engine containing at least one machine learning model trained to predict personalized three-dimensional radiotherapy dose distributions and dose-volume histograms from the preprocessed data; • an adaptation module to receive updated clinical data and automatically adapt the dosing schedule to intra-fraction and inter-fraction changes in patient anatomy and response to treatment; • a clinician dashboard that displays predicted dosing schedules, allows clinician interaction, and can make the model interpretable through explainable AI; • a data security and compliance layer that protects data through encryption, access control, and regulatory compliance.
Owner:KHOGALI WADAH +2

Methods of treating CD20 expressing b-cell cancers

The present invention relates to improved methods for reducing cytokine release syndrome following interruption of the epcoritamab dosing schedule for the treatment of CD20 B-cell expressing cancers.
Owner:GENMAB AS

Methods for treating multiple myeloma

Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a bi-weekly dosing schedule.
Owner:JANSSEN BIOTECH INC

Caregiver system and method for interfacing with and controlling a medication dispensing device

The present disclosure provides a caregiver system and method for interfacing with and controlling an oral medication dispensing device. The system registers the caregiver and provides the caregiver a list of patients under the caregiver's care, as well as associated medication dose schedules for each of the one or more patients. The caregiver is provided reminders regarding doses and allowed to modify the dose schedule to generate a modified dose schedule. The modified does schedule is pushed to a patient system associated with a medication dispensing device.
Owner:ASPARGO LABS INC

Caregiver system and method for interfacing with and controlling a medication dispensing device

The present disclosure provides a caregiver system and method for interfacing with and controlling an oral medication dispensing device. The system registers the caregiver and provides the caregiver a list of patients under the caregiver's care, as well as associated medication dose schedules for each of the one or more patients. The caregiver is provided reminders regarding doses and allowed to modify the dose schedule to generate a modified dose schedule. The modified does schedule is pushed to a patient system associated with a medication dispensing device.
Owner:ASPARGO LABS INC

Patient system and method for interfacing with and controlling a medication dispensing device

The present disclosure provides a patient system and method for interfacing with and controlling an oral medication dispensing device. The system registers the dispensing device to a particular patient and records biometric data regarding the patient. Upon verifying a dose schedule and biometric authentication of the patient, the system authorizes use of the medication dispensing device and causes an activator mechanism to activate. In doing so, an activator mechanism within the dispensing device moves a medication cartridge between a stored position and a dispensing position, where it can be compressed to safely and efficiently dispense medication to the patient.
Owner:ASPARGO LABS INC

Methods for treating multiple myeloma

Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a monthly dosing schedule.
Owner:JANSSEN BIOTECH INC

Compositions and methods for cancer immunotherapy

PendingUS20250032582A1Peptide/protein ingredientsAntibody ingredientsMultiple administrationOncology
The disclosure provides compositions and improved methods for the treatment of cancer comprising administering to a patient the fusion protein of SEQ ID NO: 1 at a less frequent dosing schedule (i.e., a single administration every three weeks or multiple administrations on non-consecutive days).
Owner:MURAL ONCOLOGY INC

Methods for treating age-related macular degeneration

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and / or 12 weeks.
Owner:NOVARTIS PHARMA AG

Systems and methods for facilitating medicament administration

A non-transitory computer readable storage medium comprising instructions that, when executed by a computer, cause the computer to execute a program for managing a user's medical condition or treatment; monitor a current dosing schedule set within the program; determine whether a scheduled dose is due; determine an experience level of a user; in response to determining that the scheduled dose is due, generate a first notification alerting the user to the scheduled dose; and in response to detecting user interaction with the first notification, provide a user interface displaying content relating to the scheduled dose. At least part of the content displayed is based on the experience level of the user.
Owner:SANOFI SA(FR)

Systems and methods for monitoring a medicament dosing schedule

PCT designated stage expiredWO2025088063A2Drug and medicationsSensorsUser deviceEngineering
A non-transitory computer readable storage medium, user device and method configured to execute a program for managing a user's medical condition or treatment. When the program determines that a time period for taking a scheduled dose has been exceeded by more than a lower threshold time, it causes a late dose notification to be displayed. When a user interacts with the late dose notification, the program provides options for the user to (i) indicate that they have taken the scheduled dose or (ii) indicate that they have not taken the scheduled dose. When the user indicates that they have taken the scheduled dose after the lower threshold time, the program provides options for the user to (i) reset the current medicament dosing schedule or (ii) maintain the current medicament dosing schedule.
Owner:SANOFI SA(FR)

Preventive Prescription Medication Combination Pack

Preventive prescription medication combination packs offer a proactive approach to healthcare, integrating multiple medications into a single, convenient package and its given in the start of a disease, combining medications enhances adherence by simplifying complex medication regimens, reducing pill burden, and streamlining dosing schedules. This approach is particularly advantageous for preventive care, ensuring consistent medication intake and maximizing therapeutic outcomes because its used for many diseases. Preventive combination packs improve patient convenience, reducing the need for multiple pharmacy visits and minimizing the risk of medication errors. Additionally, they facilitate better communication between patients and healthcare providers, fostering a collaborative approach to treatment.
Owner:DEBONS JOSEPH MICHAEL

Methods to modify behaviors to mitigate impact of prediction inaccuracies for later time windows in AMD systems

Exemplary embodiments relate to automated medicament delivery (AMD) devices. Such devices may measure the level of an analyte and deliver medicament with the intent of maintaining the analyte at a target level or in a target range. The described methods and apparatuses apply a model to evaluate an effect of proposed future medicament doses on predicted analyte levels. The proposed future medicament doses and predicted analyte levels may be supplied to a cost function to select which of the proposed future medicament dose schedules results in optimal control of the predicted analyte levels. The cost function may apply a weighting scheme that weighs predictions in the near- and / or medium-term future more than longer-term predictions.
Owner:INSULET CORP

Methods for treating multiple myeloma

Embodiments of the invention relate to methods of treating multiple myeloma in a subject in need thereof, the method comprising administering to the subject a BCMAxCD3 bispecific antibody on a monthly dosing schedule.
Owner:JANSSEN BIOTECH INC

Therapeutic and / or prophylactic agent for mycosis containing isavuconazole or prodrug thereof as active ingredient

To provide a therapeutic and / or prophylactic agent for mycosis, which is excellent in safety and effectiveness, is administered to a Japanese mycosis patient, and contains isavuconazole or a prodrug thereof as an active ingredient.SOLUTION: A therapeutic and / or prophylactic agent for mycosis, which is administered according to a loading dosing regimen, and further administered according to a maintenance dosing regimen after a lapse of 12 to 24 hours from the end of the loading dosing regimen. (1) Loading dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion every 8 hours for a total of 6 times (2) Maintenance dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion once a day in terms of isavuconazole per dose.SELECTED DRAWING: Figure 1
Owner:ASAHI KASEI PHARMA CORP

Patient system and method for interfacing with and controlling a medication dispensing device

The present disclosure provides a patient system and method for interfacing with and controlling an oral medication dispensing device. The system registers the dispensing device to a particular patient and records biometric data regarding the patient. Upon verifying a dose schedule and biometric authentication of the patient, the system authorizes use of the medication dispensing device and causes an activator mechanism to activate. In doing so, an activator mechanism within the dispensing device moves a medication cartridge between a stored position and a dispensing position, where it can be compressed to safely and efficiently dispense medication to the patient.
Owner:ASPARGO LABS INC

Administration of c5-binding proteins

Methods are described for administering a C5-binding protein to a subject. The methods include subcutaneously administering a pharmaceutical composition comprising a C5-binding protein to a subject in certain amounts and / or using certain dosing schedules to reduce the amount of free C5 in the subject and / or inhibit terminal complement activity in the subject.
Owner:IPC RESEARCH LLC

Methods of treating neoplastic diseases

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in the claims for use in the treatment of a neoplastic disease in a subject, wherein said treatment comprises administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to the subject according to an intermittent dosing schedule.
Owner:SILLAJEN INC

Methods for treating multiple myeloma

Embodiments of the invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a GPRC5DxCD3 bispecific antibody according to a monthly administration schedule.
Owner:JANSSEN BIOTECH INC

HDAC inhibitor OKI-179 in combination with binimetinib for the treatment of cancer

A method of treating cancer in a subject in need thereof, wherein the method comprises administration of therapeutically effective amounts of OKI-179 and binimetinib or a pharmaceutically acceptable salt thereof, or administration of therapeutically effective amounts of OKI-179, binimetinib or a pharmaceutically acceptable salt thereof, and encorafenib or a pharmaceutically acceptable salt thereof according to the dosing schedules described herein.
Owner:ONKURE INC +1

Improved aromatase inhibitor dosing schedules and compositions

Provided are improved dosing schedules and compositions for the intramuscular administration of compositions containing aromatase inhibitors such as letrozole, for use in treating letrozole-sensitive diseases, conditions or disorders. In the dosing schedules, a first dose of long-acting injectable composition is administered and after a delay period, a second dose of long-acting injectable composition is administered, which provides overlapping dosing periods and improves oestrogen suppression.
Owner:LAB FARM ROVI SA

Methods for treating age-related macular degeneration

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and / or 12 weeks.
Owner:NOVARTIS AG

Medical use of CCR8 antibodies and dosing schedule

The present invention relates to medical uses comprising the administration of anti-human CCR8 antibodies in specifically defined dosage regimens in monotherapy or combination therapy with an anti-PD-(L)1 antibody. The dosing schemes were developed for anti-human / cynomolgus CCR8 antibody TPP-23411, but they can also be used for other antibodies having similar properties as TPP-23411. The medical uses or dosage regimens may comprise a stratification step to select patients with an increased probability of treatment success. Suggested biomarkers are a) Tumor Proportion Score or Combined Positive Score as a measure for PD-(L)1 expression, b) analysing in a blood, plasma or serum sample inflammatory cytokines and c) previous treatment of the cancer for at least 6 months with an anti-PD-(L)1 antibody. Furthermore, provided are anti-human CCR8 antibody-based medical uses and treatment methods comprising the administration of a Zr-89-labeled anti-CD8 minibody to determine the abundance and / or distribution of CD8 cells by means of a PET scan for stratification or for monitoring treatment success or disease progression. Also provided is a method to reliably determine an anti-anti-CCR8 antibody in cynomolgus or human plasma. Finally, an anti-murine CCR8 surrogate antibody is disclosed that mimics the unusual half-life of TPP-23411.
Owner:BAYER AG +1

Compounds for nos-related cancers and methods of use

Disclosed herein are novel NOS inhibitor compounds. Also disclosed herein, are methods for treating, ameliorating, and / or reducing the severity of NOS-related cancer, or a symptom associated therewith in a subject. The compounds described herein may be administered with a particular route of delivery, dosing regimen, and dosing schedule.
Owner:YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD

Patient system and method for interfacing with and controlling a medication dispensing device

The present disclosure provides a patient system and method for interfacing with and controlling an oral medication dispensing device. The system registers the dispensing device to a particular patient and records biometric data regarding the patient. Upon verifying a dose schedule and biometric authentication of the patient, the system authorizes use of the medication dispensing device and causes an activator mechanism to activate. In doing so, an activator mechanism within the dispensing device moves a medication cartridge between a stored position and a dispensing position, where it can be compressed to safely and efficiently dispense medication to the patient.
Owner:ASPARGO LABS INC

System and method for monitoring medicament administration schedule

A non-transitory computer-readable storage medium, a user device, and a method configured to execute a program for managing a medical condition or treatment of a user are provided. When the procedure determines that the period of time for taking the predetermined dose has been exceeded by more than a lower threshold time, the procedure causes a late dose notification to be displayed. When a user interacts with the late dose notification, the program provides the user with an option to (i) indicate that they have taken the predetermined dose or (ii) indicate that they have not taken the predetermined dose. When the user indicates that they have taken the predetermined dose after the lower threshold time, the procedure provides the user with an option to (i) reset the current medicament administration schedule or (ii) maintain the current medicament administration schedule.
Owner:SANOFI SA(FR)

Intervention method for relieving T-2 toxin induced cellular immune aging based on PER2 protein inhibition and application thereof

The invention relates to the cross field of toxicology and immunology, in particular to an intervention method for relieving T-2 toxin induced cellular immune aging based on PER2 protein inhibition and application of the intervention method. The method comprises the following steps: S1, providing an exposed object containing immune cells in an in-vitro culture system; s2, firstly applying a PER2 inhibitor; s3, sequentially finishing S2 and T-2 treatment according to a preset initial administration time interval; and S4, characterizing the Hippo pathway MST1 / YAP / p-YAP in 4 hours and / or 12 hours after T-2 treatment, and obtaining p-YAP subcellular localization, thereby determining or adjusting the administration time course. According to the scheme, closed-loop standard operation and parameter setting are carried out according to'administration-detection-time history determination '.
Owner:YANGTZE UNIVERSITY